

STEFANIA TACCONELLI

Researcher unique identifier (ORCID): 0000-0003-4907-1822

Personal Information

Stefania Tacconelli

Department of Neuroscience, Imaging and Clinical Sciences, Section of Cardiovascular and Pharmacological Sciences and CAST (Center for Advanced Studies and Technology), University "G. d'Annunzio" Chieti, Via dei Vestini, 31, 66100, Chieti, Italy.

Phone: +390871541471

Email: s.tacconelli@unich.it

Education and Qualifications

1998: Graduated cum laude in Pharmaceutical Chemistry and Technology at the Faculty of Pharmacy, "G. D'Annunzio" University of Chieti. Title of thesis: Effect of Vitamin E on the biosynthesis of isoprostane: a marker of lipid peroxidation in vivo.

1999-2000: Fellowship at the Section of Pharmacology under the supervision of Prof Paola Patrignani (Section of Pharmacology of "G. D'Annunzio" University in Chieti)

2000-2004: She attended a PhD course in Science of Aging, at the laboratories of the Section of Pharmacology of "G. D'Annunzio" University in Chieti, tutor: Prof Patrignani

December 2004: PhD degree in Science of Aging with a thesis entitled: "Isoprostanes as indices of lipid peroxidation in cardiovascular diseases"

May 2005-December 2008: Post-doc fellowship entitled "Genetic polymorphisms and cardiovascular protection"

Employment and Academic Ranks

December 2008-ongoing: Assistant Professor of Pharmacology, Department of Neuroscience, Imaging and Clinical Sciences, "G. d'Annunzio" University, Chieti, Italy.

2012-2017: Member of the Board of the Department of Neuroscience, Imaging and Clinical Sciences of the University "G. D'Annunzio" of Chieti.

2013-2018: Member of Academic Board of PhD Course in "Medical Biotechnologies", "G. D'Annunzio" University, Chieti, Italy

2019-2020: Member of the Board of the Department of Neuroscience, Imaging and Clinical Sciences of the University "G. D'Annunzio" of Chieti.

2021-ongoing: Member of Academic Board of PhD Course in "Medical Biotechnologies", "G.

D'Annunzio" University, Chieti, Italy

Honors and Awards

1993-1998, Scholarship by Azienda per il diritto Agli Studi Universitari di Chieti (ADSU), Chieti

2013, Results of VQR of her publications were evaluated as “excellent”

2017, Results of VQR of her publications were evaluated as “excellent”

2017, “Annual individual funding of basic research activities” by MIUR.

Memberships in Scientific Societies

Italian Society of Pharmacology

Scopus Parameters with date

H index: 32 (29/6/2021)

Citation: 3493 (29/6/2021)

Patents

1. Italian patent (n. MI2004A000019) entitled: “DERIVATI ISOSSAZOLICI E LORO IMPIEGO COME INIBITORI DELLA CICLOOSSIGENASI” deposited on 12/01/2004. Inventors: Scilimati A, Vitale P, Di Nunno L, Patrignani P, Tacconelli S.
2. Italian patent (n.MI2005A001320) entitled: “DIARILISOSSAZOLI FUNZIONALIZZATI INIBITORI DELLA CICLOOSSIGENASI” deposited on 12/07/2005. Inventors: Scilimati A, Vitale P, Di Nunno L, Patrignani P, Capone ML. Tacconelli S.
3. European patent n. 05702217.0 entitled: “ISOXAZOLE DERIVATIVES AND THEIR USE AS CYCLOOXYGENASE INHIBITORS” deposited on 24/3/2007. Inventors: Scilimati A, Vitale P, Di Nunno L, Patrignani P, Tacconelli S, Stuppia L, Porreca E.
4. Divisional European patent entitled: “ISOXAZOLE DERIVATIVES AND THEIR USE AS CYCLOOXYGENASE INHIBITORS”, n. 10005150.7 deposited on 12/01/2005. Inventors: Scilimati A, Vitale P, Di Nunno L, Patrignani P, Tacconelli S, Stuppia L, Porreca E.
5. Patent application in USA n. 12/007,571 “Functionalized diarylisoxazoles inhibitors of cyclooxygenase” (published on 02/08/2011). Inventors: Scilimati A, Di Nunno L, Vitale P, Patrignani P, Tacconelli S, Capone ML.

Original Peer-Reviewed Publications (total)

1. Panara MR, Renda G, Sciulli MG, Santini G, Di Giamberardino M, Rotondo MT, **Tacconelli S**, Seta F, Patrono C, Patrignani P. Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. **J Pharmacol Exp Ther.**290; 276-80, 1999.

2. Patrignani P, Panara MR, **Tacconelli S**, Seta F, Bucciarelli T, Ciabattoni G, Alessandrini P, Mezzetti A, Santini G, Sciulli MG, Cipollone F, Davi' G, Gallina P, Bittolo Bon G, Patrono C. Effects of Vitamin E supplementation on F₂-isoprostanes and thromboxane biosynthesis in healthy cigarette smokers. **Circulation**, **102**; **539-545**, **2000**.
3. Santini G, Patrignani P, Sciulli MG, Seta F, **Tacconelli S**, Panara MR., Ricciotti E, Capone ML, Patrono C. The human pharmacology of monocyte COX-2 inhibition by cortisol and synthetic glucocorticoids. **Clin Pharmacol Ther.****70(5): 475-83**, **2001**.
4. **Tacconelli S**, Capone ML, Sciulli MG, Ricciotti E, Patrignani P. The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity. **Curr. Med. Res. Opin.** **18: 503-511**, **2002**.
5. Minuz P, Patrignani P, Gaino S, Degan M, Menapace L, Tommasoli R., Seta F, Capone ML, **Tacconelli S**, Palatresi S, Bencini C, Del Vecchio C, Mansueto GC, Arosio C, Santonastaso Lechi C, Lechi C, Morganti A, Patrono C. Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. **Circulation** **106: 2800-2805**, **2002**.
6. Sciulli MG, Seta F, **Tacconelli S**, Ricciotti E, Capone ML, Patrignani P. Effects of acetaminophen on constitutive and inducible prostanoid biosynthesis in human blood cells. **Br. J. Pharmacol.** **138: 634-641**, **2003**.
7. Patrignani P, Capone ML, **Tacconelli S**. Clinical pharmacology of etoricoxib: a novel selective COX-2 inhibitor. **Expert Opin Pharmacother.** **4: 265-284**, **2003**.
8. Capone ML, **Tacconelli S**, Sciulli MG, Patrignani P. Clinical pharmacology of selective COX-2 inhibitors. **Int. J. Immunopathol. Pharmacol.** **16: 49-58**, **2003**.
9. **Tacconelli S**, Capone ML, Patrignani P. Clinical pharmacology of novel selective COX-2 inhibitors. **Current Pharmaceutical Design** **10(6):589-601**, **2004**.
10. Minuz P, Patrignani P, Gaino S, Seta F, Capone ML, **Tacconelli S**, Degan M, Faccini G, Fornasiero A, Talamini G, Tommasoli R, Arosio E, Santonastaso CL, Lechi A, Patrono C. Determinants of platelet activation in human essential hypertension. **Hypertension** **43(1):64-70**, **2004**.
11. Capone ML, **Tacconelli S**, Sciulli MG, Grana M, Ricciotti E, Minuz P, Di Gregorio P, Merciaro G, Patrono C, Patrignani P. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. **Circulation** **109(12):1468-71**, **2004**.
12. Di Nunno L, Vitale P, Scilimati A, **Tacconelli S**, Patrignani P. Novel Synthesis of 3,4-diarylisoaxazole Analogues of Valdecoxib: Reversal COX-2 Selectivity by Sulfonamide Group Removal. **J. Med. Chem** **47(20): 4881-90**, **2004**.

13. Patrignani P, **Tacconelli S**, Sciulli MG, Capone ML. New insights into COX-2 biology and inhibition. **Brain Res Rev. 2: 352-359, 2005.**
14. Sciulli MG, Filabozzi P, **Tacconelli S**, Padovano R, Ricciotti E, Capone ML, Grana M, Carnevale V, Patrignani P. Platelet activation in patients with colorectal cancer. **Prostaglandins Leukot Essent Fatty Acids, 72(2):79-83, 2005.**
15. Capone ML, Sciulli MG, **Tacconelli S**, Grana M, Ricciotti E, Di Gregorio P, Merciaro G, Renda G, Patrignani P. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. **J Am Coll Cardiol. 45: 1295-301, 2005.**
16. Sciulli MG, Capone ML, **Tacconelli S**, Patrignani P. The future of traditional nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors in the treatment of inflammation and pain. **Pharmacol Rep ;57 Suppl:66-85, 2005.**
17. Capone ML, **Tacconelli S**, Patrignani P. Clinical pharmacology of etoricoxib. **Expert Opin Drug Metab Toxicol 1(2): 269-282, 2005.**
18. Patrignani P, **Tacconelli S**. Isoprostanes and other markers of lipid peroxidation in atherosclerosis. **Biomarkers, 10(1):S24-9, 2005.**
19. Patrignani P, Di Febbo C, **Tacconelli S**, Moretta V, Baccante G, Sciulli MG, Ricciotti E, Capone ML, Antonucci I, Guglielmi MD, Stuppia L, Porreca E. Reduced thromboxane biosynthesis in carriers of toll-like receptor 4 polymorphisms in vivo. **Blood. 2006;107(9): 3572-3574, 2006.**
20. Evangelista V, Manarini S, Di Santo A, Capone ML, Ricciotti E, Di Francesco L, **Tacconelli S**, Sacchetti A, Scilimati A, Sciulli MG, Patrignani P. De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin. **Circ Res. ;98(5): 593-595, 2006.**
21. Renda G, **Tacconelli S**, Sacchetta D, Capone ML, Santarelli F, Sciulli MG, Zimarino M, Grana M, D'Amelio E, Zurro M, Patrono C, De Caterina R, Patrignani P. Celecoxib, ibuprofen and the antiplatelet effect of aspirin in patients with osteoarthritis and chronic stable angina. **Clin Pharmacol Ther. 80(3):264-274, 2006.**
22. Sciulli MG, Renda G, Capone ML, **Tacconelli S**, Ricciotti E, Manarini S, Evangelista V, Rebuzzi AG, Patrignani P. Heterogeneity in the extinguishments of platelet cyclooxygenase-1 activity by aspirin in cardiovascular disease. **Clin Pharmacol Ther.80:115-125, 2006.**
23. Capone ML, **Tacconelli S**, Di Francesco L, Sacchetti A, Sciulli MG, Paola Patrignani. Pharmacodynamic of cyclooxygenase inhibitors in humans. **Prostaglandins Other Lipid Mediat. 82:85-94, 2007.**
24. Capone ML*, **Tacconelli S***, Sciulli MG, Anzellotti P, Di Francesco L, Merciaro G, Di

- Gregorio P, Patrignani P. Human pharmacology of naproxen sodium. **J Pharmacol Exp Ther.** **322**; 453-460, 2007.
25. Capone ML*, **Tacconelli S***, Di Francesco L, Petrelli M, Patrignani P. Cardiovascular effects of valdecoxib: transducing human pharmacology results into clinical read-outs. **Expert Opin Drug Saf.** **7(1):29-42, 2008.**
26. Patrignani P, Capone ML, **Tacconelli S.** NSAIDs and cardiovascular disease. **Heart.** **94(4):395-7, 2008.**
27. Minuz P, Jiang H, Fava C, Turolo L, **Tacconelli S**, Ricci M, Patrignani P, Morganti A, Lechi A, McGiff JC. Altered Release of Cytochrome P450 Metabolites of Arachidonic Acid in Renovascular Disease. **Hypertension.** **51: 1379-1385, 2008.**
28. Patrignani P, Di Febbo C, **Tacconelli S**, Douville K, Guglielmi MD, Horvath RJ, Ding M, Sierra K, Stitham J, Gleim S, Baccante G, Moretta V, Di Francesco L, Capone ML, Porreca E, Hwa J. Differential association between human prostacyclin receptor polymorphisms and the development of venous thrombosis and intimal hyperplasia: a clinical biomarker study. **Pharmacogenetics and Genomics, 18: 611-620, 2008**
29. García Rodríguez LA, Tacconelli S, **Patrignani P.** Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. **J Am Coll Cardiol, 52:1628-36, 2008**
30. Patrignani P, **Tacconelli S**, Capone ML. Risk management profile of etoricoxib: an example of personalized medicine. **Ther Clin Risk Manag,4(5):983-97, 2008.**
31. Bruno A, Di Francesco L, Coletta I, Mangano G, Alisi MA, Polenzani L, Milanese C, Anzellotti P, Ricciotti E, Dovizio M, Di Francesco A, **Tacconelli S**, Capone ML, Patrignani P. Effects of AF3442 [N-(9-ethyl-9H-carbazol-3-yl)-2-(trifluoromethyl)benzamide], a novel inhibitor of human microsomal prostaglandin E synthase-1, on prostanoid biosynthesis in human monocytes in vitro. **Biochem Pharmacol, 79(7):974-81, 2010.**
32. Massó González E*, Patrignani P*, **Tacconelli S**, García Rodríguez LA. Variability of risk of upper gastrointestinal bleeding among nonsteroidal anti-inflammatory drugs. **Arthritis & Rheumatism 62(6):1592-601, 2010. *equal contribution**
33. Capone ML, **Tacconelli S**, Rodriguez LG, Patrignani P. NSAIDs and cardiovascular disease: transducing human pharmacology results into clinical read-outs in the general population. **Pharmacol Rep. 62(3):530-5, 2010.**
34. **Tacconelli S**, Capone ML, Patrignani P. Measurement of 8-iso-prostaglandin F2alpha in biological fluids as a measure of lipid peroxidation. **Methods Mol Biol. 644:165-78, 2010**

35. Patrignani P, **Tacconelli S**, Bruno A. Grand challenges in pharmacotherapy of inflammation for the first decades of the 21st century. **Front Pharmacol.** **2010;1:2.**
36. Anzellotti P, Capone ML, Jeyam A, **Tacconelli S**, Bruno A, Tontodonati P, Di Francesco L, Grossi L, Renda G, Merciaro G, Di Gregorio P, Price TS, Garcia Rodriguez LA, Patrignani P. Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences. **Arthritis Rheum** **63(3):850-9, 2011.**
37. Biava M, Porretta GC, Poce G, Battilocchio C, Botta M, Manetti F, Rovini M, Cappelli A, Sautebin L, Rossi A, Pergola C, Ghelardini C, Galeotti N, Makovec F, Giordani A, Anzellotti P, **Tacconelli S**, Patrignani P, Anzini M. Enlarging the NSAIDs family: ether, ester and acid derivatives of the 1,5-diarylpyrrole scaffold as novel anti-inflammatory and analgesic agents. **Curr Med Chem.** **18(10):1540-54, 2011.**
38. Patrignani P, **Tacconelli S**, Bruno A, Sostres C, Lanas A. Managing the adverse effects of nonsteroidal anti-inflammatory drugs. **Exp Rev Clin Pharmacol,** **4:605-621, 2011.**
39. Tang WH, Stitham J, Gleim S, Di Febbo C, Porreca E, Fava C, **Tacconelli S**, Capone M, Evangelista V, Levantesi G, Wen L, Martin K, Minuz P, Rade J, Patrignani P, Hwa J. Glucose and collagen regulate human platelet activity through aldose reductase induction of thromboxane. **J Clin Invest.** **121(11): 4462-76, 2011.**
40. Cesari M, Kritchevsky SB, Nicklas B, Kanaya AM, Patrignani P, **Tacconelli S**, Tranah GJ, Rognoni G, Harris TB, Antonelli Incalzi R, Newman AB, Pahor M, for the Health ABC study. **J Gerontol A Biol Sci Med Sci.** **67A(6):671-676, 2012.**
41. Dovizio M, **Tacconelli S**, Sostres C, Ricciotti E, Patrignani P. Mechanistic and Pharmacological Issues of Aspirin as an Anticancer Agent. **Pharmaceuticals** **2012, 5, 1346-1371**
42. Dovizio M*, **Tacconelli S***, Ricciotti E*, Bruno A, Maier TJ, Anzellotti P, Di Francesco L, Sala P, Signoroni S, Bertario L, Dixon DA, Lawson JA, Steinhilber D, FitzGerald GA, Patrignani P. Effects of celecoxib on prostanoid biosynthesis and circulating angiogenesis proteins in familial adenomatous polyposis. **J Pharmacol Exp Ther.** **341(1):242-50, 2012.**
43. Marcantoni E, Di Francesco L, Totani L, Piccoli A, Evangelista V, **Tacconelli S**, Patrignani P. Effects of estrogen on endothelial prostanoid production and cyclooxygenase-2 and heme oxygenase-1 expression. **Prostaglandins Other Lipid Mediat.** **2012 Feb 6. [Epub ahead of print]**
44. Bruno A, Dovizio M, **Tacconelli S**, Patrignani P. Mechanisms of the antitumoural effects of aspirin in the gastrointestinal tract. **Best Pract Res Clin Gastroenterol.** **2012;26(4):e1-e13.**

45. Garcia Rodriguez LA, Cea-Soriano L, **Tacconelli S**, Patrignani P. Coxibs: pharmacology, toxicity and efficacy in cancer clinical trials. **Recent Results Cancer Res.** 2013;**191:67-93**.
46. Dovizio M, Bruno A, **Tacconelli S**, Patrignani P. Mode of action of aspirin as a chemopreventive agent. **Recent Results Cancer Res.** 2013;**191:39-65**.
47. Maenthaisong R*, **Tacconelli S***, Sritara P, Del Boccio P, Di Francesco L, Sacchetta P, Archararit N, Aryurachai K, Patrignani P, Suthisisang C. Clinical pharmacology of cyclooxygenase inhibition and pharmacodynamic interaction with aspirin by floctafenine in Thai healthy subjects. **Int J Immunopathol Pharmacol.** 2013;**26(2):403-17**.
48. Vitale P*, **Tacconelli S***, Perrone MG, Malerba P, Simone L, Scilimati A, Lavecchia A, Dovizio M, Marcantoni E, Bruno A, Patrignani P. Synthesis, pharmacological characterization, and docking analysis of a novel family of diarylisoxazoles as highly selective cyclooxygenase-1 (COX-1) inhibitors. **J Med Chem.** 2013;**56(11):4277-99**.
49. Bruno A, **Tacconelli S**, Patrignani P. Variability in the Response to Non-Steroidal Anti-Inflammatory Drugs: Mechanisms and Perspectives. **Basic Clin Pharmacol Toxicol.** 2014;**114(1):56-63**.
50. Patrignani P, **Tacconelli S**, Piazuolo E, Di Francesco L, Dovizio M, Sostres C, Marcantoni E, Guillem-Llobat P, Del Boccio P, Zucchelli M, Patrono C, Lanas A. Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action. **J Thromb Haemost.** 2014; **12(8):1320-3**.
51. Patrignani P, **Tacconelli S**, Bruno A. Gut microbiota, host gene expression, and aging. **J Clin Gastroenterol.** 2014;**48 Suppl 1:S28-31**.
52. **Tacconelli S**, Patrignani P. Inside epoxyeicosatrienoic acids and cardiovascular disease. **Front Pharmacol.** 2014;**5:239**.
53. Di Francesco L, Dovizio M, Trenti A, Marcantoni E, Moore A, O'Gaora P, McCarthy C, **Tacconelli S**, Bruno A, Alberti S, Gizzo S, Nardelli GB, Orso G, Belton O, Trevisi L, Dixon DA, Patrignani P. Dysregulated post-transcriptional control of COX-2 gene expression in gestational diabetic endothelial cells. **Br J Pharmacol.** 2015; **172(18): 4575–4587**.
54. Patrignani P, Sacco A, Sostres C, Bruno A, Dovizio M, Piazuolo E, Di Francesco L, Contursi A, Zucchelli M, Schiavone S, **Tacconelli S**, Patrono C, Lanas A. Low-dose aspirin acetylates cyclooxygenase-1 in human colorectal mucosa: implications for the chemoprevention of colorectal cancer. **Clin Pharmacol Ther.** 2017 ;**102(1):52-61**
55. **Tacconelli S**, Bruno A, Grande R, Ballerini P, Patrignani P. Nonsteroidal anti-inflammatory drugs and cardiovascular safety - translating pharmacological data into clinical readouts. **Expert Opin Drug Saf.** 2017;**16(7):791-807**.

56. Ballerini P, Dovizio M, Bruno A, **Tacconelli S**, Patrignani P. P2Y₁₂ Receptors in Tumorigenesis and Metastasis. **Front Pharmacol.** **2018;9:66.**
57. **Tacconelli S***, Dovizio M,* Di Francesco L, Meneguzzi A, D'Agostino I, Evangelista V, Manarini S, Capone ML, Grossi L, Porreca E, Di Febbo C, Bruno A, Ballerini P, Levantesi G, Fava C, Minuz P, Patrignani P. Reduced variability to aspirin antiplatelet effect by the coadministration of statins in high-risk patients for cardiovascular disease. **Clin Pharmacol Ther.** **2018; 104(1): 111-119.**
58. Bruno A, Dovizio M, **Tacconelli S**, Contursi A, Ballerini P, Patrignani P. Antithrombotic Agents and Cancer. **Cancers (Basel).** **2018;10(8).**
59. Saul MJ*, Baumann I*, Bruno A*, Emmerich AC, Wellstein J, Ottinger SM, Contursi A, Dovizio M, Donnini S, **Tacconelli S**, Raouf J, Idborg H, Stein S, Korotkova M, Savai R, Terzuoli E, Sala G, Seeger W, Jakobsson PJ, Patrignani P, Suess B, Steinhilber D. miR-574-5p as RNA decoy for CUGBP1 stimulates human lung tumor growth by mPGES-1 induction. **FASEB J.** **2019 Mar 28:fj201802547R.**
60. Sacco A*, Bruno A*, Contursi A, Dovizio M, **Tacconelli S**, Ricciotti E, Guillem-Llobat P, Salvatore T, Di Francesco L, Fullone R, Ballerini P, Arena V, Alberti S, Liu G, Gong Y, Sgambato A, Patrono C, FitzGerald GA, Yu Y, Patrignani P. Platelet-Specific Deletion of Cyclooxygenase-1 Ameliorates Dextran Sulfate Sodium-Induced Colitis in Mice. **J Pharmacol Exp Ther.** **2019; 370(3):416-426.**
61. Di Francesco L*, Bruno A*, Ricciotti E*, **Tacconelli S**, Dovizio M, Guillem-Llobat P, Alisi MA, Garrone B, Coletta I, Mangano G, Milanese C, FitzGerald GA, Patrignani P. Pharmacological characterization of the microsomal prostaglandin E₂ synthase-1 inhibitor AF3485 in vitro and in vivo. **Frontiers in Pharmacology** **2020;11:374**
62. **Tacconelli S***, Contursi A*, Falcone L, Mucci M, D'Agostino I, Fullone R, Sacco A, Zucchelli M, Bruno A, Ballerini P, Dovizio M, Patrignani P. Characterization of cyclooxygenase-2 acetylation and prostanoid inhibition by aspirin in cellular systems. **Biochem Pharmacol.** **2020;178:114094.**
63. **Tacconelli S***, Fullone R*, Dovizio M*, Pizzicoli G, Marschler S, Bruno A, Zucchelli M, Contursi A, Ballerini P, Patrignani P. Pharmacological characterization of the biosynthesis of prostanoids and hydroxyeicosatetraenoic acids in human whole blood and platelets by targeted chiral lipidomics analysis. **Biochim Biophys Acta Mol Cell Biol Lipids.** **2020;1865(12):158804.**
64. Alberti S*, Zhang Q*, D'Agostino I*, Bruno A, **Tacconelli S**, Contursi A, Guarnieri S, Dovizio M, Falcone L, Ballerini P, Münch G, Yu Y, Patrignani P. The antiplatelet agent

- Revacept prevents the increase of systemic thromboxane A2 biosynthesis and neointima hyperplasia. **Sci Rep. 2020;10(1):21420.**
65. Dovizio M*, Ballerini P*, Fullone R, Tacconelli S, Contursi A, Patrignani P. Multifaceted Functions of Platelets in Cancer: From Tumorigenesis to Liquid Biopsy Tool and Drug Delivery System. **Int J Mol Sci. 2020;21(24):9585.**
66. Balduini A, Fava C, Di Buduo CA, Abbonante V, Meneguzzi A, Soprano PM, Taus F, Castelli M, Giontella A, Dovizio M, **Tacconelli S**, Patrignani P, Minuz P. Expression and functional characterization of the large-conductance calcium and voltage-activated potassium channel $K_{CA} 1.1$ in megakaryocytes and platelets. **J Thromb Haemost. 2021 Feb 16.**
67. D'Agostino I*, **Tacconelli S***, Bruno A*, Contursi A, Mucci L, Hu X, Xie Y, Chakraborty R, Jain K, Sacco A, Zucchelli M, Landolfi R, Dovizio M, Falcone L, Ballerini P, Hwa J, Patrignani P. Low-dose Aspirin prevents hypertension and cardiac fibrosis when thromboxane A2 is unrestrained. *Pharmacol Res.*2021 Jun 25:105744.

I authorize the processing of my personal data pursuant to Legislative Decree 30 June 2003, n. 196

"Code regarding the protection of personal data"



Chieti, 29/6/2021